Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
Do Diuretics, Beta-Blockers, a...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
Detalles Bibliográficos
Main Authors:
Shen, L
,
Shah, B
,
Reyes, E
,
Thomas, L
,
Diem, P
,
Leiter, L
,
Charbonnel, B
,
Mareev, V
,
Horton, E
,
Haffner, S
,
Soska, V
,
Holman, R
,
Bethel, M
,
Schaper, F
,
Sun, J
,
McMurray, J
,
Califf, R
,
Krum, H
Formato:
Journal article
Publicado:
2012
Existencias
Descripción
Títulos similares
Staff View
Títulos similares
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
por: Shen, L, et al.
Publicado: (2013)
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
por: Mcmurray, J, et al.
Publicado: (2012)
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
por: McMurray, J, et al.
Publicado: (2012)
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
por: Krum, H, et al.
Publicado: (2010)
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
por: Califf, R, et al.
Publicado: (2008)